LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Autoantibody against Septin-3 Discovered in Neurological Disease

By LabMedica International staff writers
Posted on 27 Apr 2023
Image: septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes (Photo courtesy of EUROIMMUN)
Image: septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes (Photo courtesy of EUROIMMUN)

Septins are cytoskeletal proteins that play multiple roles in cell division, cellular polarization, morphogenesis, and membrane trafficking. Septin-5 and septin-7 are already known target antigens of autoantibodies in neurological diseases. Now, scientists have discovered autoantibodies against septin-3 in patients with paraneoplastic cerebellar ataxia.

In a collaborative study between EUROIMMUN (Lübeck, Germany), the University of Heidelberg (Heidelberg, Germany), and other German clinics, researchers analyzed three patient sera with similar immunofluorescence staining patterns on cerebellar and hippocampal sections. They identified septin-3, -5, -6, -7, and -11 as candidate target antigens using immunoprecipitation and mass spectrometry. These proteins were then expressed recombinantly in HEK293 cells either individually, as complexes, or in combinations missing individual septins. The cells were used in recombinant-cell indirect immunofluorescence assays (RC-IIFA) to detect corresponding autoantibodies.

The three patient sera reacted with recombinant cells co-expressing septin-3/5/6/7/11, while none of the control sera did. Different septin combinations confirmed the autoantibodies' specificity for septin-3. In RC-IIFA analyses, patient sera reacted only with cells expressing septin-3, either individually or in complexes. The specificity was further verified by eliminating tissue IIFA reactivity through prior neutralization of autoantibodies with recombinant septin-3. All three patients presented with progressive cerebellar syndrome and responded poorly to immunotherapy. All had cancer (2 melanomas and 1 small-cell lung cancer). Expression of septin-3 was demonstrated in resected tumor tissue available from one patient.

The authors concluded that septin-3 is a novel autoantibody target in patients with paraneoplastic cerebellar syndromes. Due to the different clinical phenotypes reported in patients with anti-septin-3, -5, and -7 autoimmunity, these autoantibodies may serve as markers for different clinical presentations. As a result, septin-3 IgG-associated autoimmune cerebellar ataxia might represent a new paraneoplastic neurological syndrome (PNS). The suggested strategy for determining anti-septin autoantibodies is RC-IIFA with the complex septin-3/5/6/7/11 as a screening tool to investigate serological samples with a characteristic staining pattern on neuronal tissue sections. Autoantibodies against individual septins can then be confirmed by RC-IIFA expressing single antigens.

Related Links:
EUROIMMUN 
University of Heidelberg

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more